Maria Watson
Rheumatology · Hope Mills, NCNPI 1033122668
Payments from drug & device makers
Across 486 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Novartis$1K
- GSK$847
- Lilly USA, LLC$768
- UCB, Inc.$626
- plus $3K from 19 others
What the payments were for
- Food & beverage$10,115100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $1,962 |
| Amgen | 85 | $1,557 |
| Novartis | 44 | $1,033 |
| GSK | 30 | $847 |
| Lilly USA, LLC | 44 | $768 |
| UCB, Inc. | 28 | $626 |
| Johnson & Johnson | 35 | $584 |
| Aurinia Pharma U.S., Inc. | 21 | $486 |
| Pfizer | 29 | $462 |
| Regeneron Healthcare Solutions, Inc. | 18 | $389 |
| AstraZeneca | 13 | $310 |
| Medexus Pharma, Inc. | 8 | $202 |
| Mallinckrodt Enterprises LLC | 4 | $126 |
| Mallinckrodt Hospital Products Inc. | 4 | $112 |
| Sanofi | 4 | $107 |
| Novo Nordisk | 5 | $93 |
| Fresenius Kabi USA, LLC | 2 | $85 |
| Radius Health, Inc. | 5 | $78 |
| Amarin Pharma, Inc. | 4 | $70 |
| Sandoz | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 3 | $67 |
| Boehringer Ingelheim | 4 | $59 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Phadia US Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,151 in reported general payments places this provider in the 65th percentile of 210 rheumatology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 47 | $339,788 |
| Enbrel SureclickEtanercept | 17 | $128,235 |
| RinvoqUpadacitinib | 14 | $90,314 |
| KevzaraSarilumab | 15 | $65,070 |
| Hydroxychloroquine Sulfate | 32 | $770 |
| Gabapentin | 23 | $471 |
| Duloxetine Hcl | 22 | $403 |
| MethotrexateMethotrexate Sodium | 15 | $288 |
| Prednisone | 20 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,962 | $90,31414 claims |
| SanofiKevzara | $107 | $65,07015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Hope Mills
- Laura SchanbergDurham$6.9M
- Rakesh PatelSalisbury$4M
- Jane BoxCharlotte$3.9M
- Gordon LamCharlotte$3.5M
- David SnowDelco$3.4M
- Alireza NamiCharlotte$3.1M
- Tauseef SyedGreensboro$1.7M
- Michael HershfieldDurham$1.5M
- Ralph SnydermanDurham$1.3M
- Megan ClowseDurham$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.